Financial Report: GlaxoSmithKline 1Q11

GlaxoSmithKline 1Q11

1Q Revenues: $10.5 billion (-9%)

1Q Earnings: $3.3 billion (flat)

Comments: Pharmaceutical sales were $8.4 billion in the quarter (-12%). Avandia sales were down 45% to $145 million. Seretide/Advair sales were flat at $2.0 billion. Flixotide/Flovent sales were $323 million (+6%). Valtrex sales were $144 million (-48%), as generics ate away at its base. Lamictal sales were $182 million (-3%). Avodart sales were $266 million (+23%). Lovaza sales were $203 million (+22%). Augmentin sales were $299 million (+20%). Vaccine sales were $1.2 billion, down 5%. Pandemic flu vaccines sales were $8.0 million in the quarter, compared to $1.1 billion in 1Q10.